LUNSUMIO DIN 02565226
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Health Canada record
| Active ingredient(s) | MOSUNETUZUMAB 1 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FX25 MOSUNETUZUMAB |
|---|
| Original market date | 05-May-2026 |
|---|
| Current status date | 05-May-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MOSUNETUZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02567369 | LUNSUMIO SC | HOFFMANN-LA ROCHE LIMITED | Solution | MOSUNETUZUMAB 5 MG | Marketed |
| 02567377 | LUNSUMIO SC | HOFFMANN-LA ROCHE LIMITED | Solution | MOSUNETUZUMAB 45 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36883 | 2026-02-06 | New Drug Submission (NDS) | |
Request a quote for LUNSUMIO
How to read a Canadian DIN record